All In Biotech

Drug Trial Radar · NCT03090100

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

Last checked: Nov 20, 2026Latest source record: Oct 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,048 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,048

Actual

Start

Apr 27, 2017

Primary completion

Aug 2, 2018

Study completion Sep 20, 2018

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.

Conditions

  • Psoriasis

Interventions

  • GuselkumabDrug

    Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.

  • PlaceboDrug

    Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.

  • SecukinumabDrug

    Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48Time frame: Week 48

Locations

142 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama

  • Southern California Permanente Medical Group

    Los Angeles, California

  • Dermatology Specialists

    Oceanside, California

  • MedDerm Associates

    San Diego, California

  • San Luis Dermatology & Laser Clinic, Inc

    San Luis Obispo, California

  • Southern California Dermatology

    Santa Ana, California

  • Clinical Research Center of Connecticut

    Danbury, Connecticut

  • Olympian Clinical Research

    Clearwater, Florida

  • Florida Academic Dermatology Centers

    Coral Gables, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Park Avenue Dermatology

    Orange Park, Florida

  • Atlanta Dermatology, Vein & Research Center

    Alpharetta, Georgia

  • Advanced Medical Research

    Atlanta, Georgia

  • Marietta Dermatology Clinical Research

    Marietta, Georgia

  • Arlington Dermatology

    Rolling Meadows, Illinois

  • Northshore Universite Healthsystem

    Skokie, Illinois

  • Dawes Fretzin Clinical Research Group

    Indianapolis, Indiana

  • Indiana Clinical Trial Center

    Plainfield, Indiana

  • Dermatology Specialists

    Louisville, Kentucky

  • DermAssociates, PC

    Rockville, Maryland

  • Great Lakes Research Group

    Bay City, Michigan

  • Henry Ford Medical Center

    Detroit, Michigan

  • Hamzavi Dermatology

    Fort Gratiot, Michigan

  • Somerset Skin Centre

    Troy, Michigan

  • Minnesota Clinical Study Center

    Fridley, Minnesota

  • Central Dermatology

    St Louis, Missouri

  • Windsor Dermatology

    East Windsor, New Jersey

  • Academic Dermatology Associates

    Albuquerque, New Mexico

  • Dermatology Consulting Services, PLLC

    High Point, North Carolina

  • Dermatologists of Greater Columbus

    Bexley, Ohio

  • The Ohio State University

    Gahanna, Ohio

  • Central Sooner Research

    Norman, Oklahoma

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • Oregon Medical Research Center

    Portland, Oregon

  • University of Pittsburgh Department of Dermatology

    Pittsburgh, Pennsylvania

  • Clinical Partners

    Johnston, Rhode Island

  • Austin Dermatology Associates

    Austin, Texas

  • Modern Research Associates

    Dallas, Texas

  • Menter Dermatology Research Institute

    Dallas, Texas

  • Suzanne Bruce and Associates - The Center for Skin Research

    Houston, Texas

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.